Merimepodib

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameMerimepodib
Drug Alias Namemerimepodibum美泊地布merimepodibMerimempodibVX-497 +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionInosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors
TargetsInosine-5'-monophosphate dehydrogenase (IMPDH)
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)HepatitisHepatitis C
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesVertex Pharmaceuticals Incorporated
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesViralclear Pharmaceuticals IncTrek TherapeuticsSorrento Therapeutics Inc +[4] 
Active IndicationsN/A
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)HepatitisHepatitis C

Other Information

ATC CodeN/A
Related LinksDrugBankKEGG